ArticleBrain sciences2019
Current Therapeutic Strategies for Glioblastoma.
Article in Brain sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 12 citations in OpenAlex.
- Promising Cancer Vaccine for Glioblastoma Therapy: A Focus on mRNA Vaccine.Cancer medicine · 2025Review
- Metabolic and physiologic magnetic resonance imaging in distinguishing true progression from pseudoprogression in patients with glioblastoma.NMR in biomedicine · 2022Review
- Somatostatin Receptor Splicing VariantInternational journal of molecular sciences · 2022Article
- Editorial: Structural, Metabolic, and Physiologic MR Imaging to Study Glioblastomas.Frontiers in neurology · 2022Article
- Predicting Survival in Glioblastoma Patients Using Diffusion MR Imaging Metrics-A Systematic Review.Cancers · 2020Review
- The Role of RNA and DNA Aptamers in Glioblastoma Diagnosis and Therapy: A Systematic Review of the Literature.Cancers · 2020Review
- Chitosan-Based Non-viral Gene and Drug Delivery Systems for Brain Cancer.Frontiers in neurology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glioblastomas (GB) are grade 4 brain tumors, one of the most aggressive forms of brain cancer found in humans. Although current treatments for GB are largely ineffective, new alternate approaches, beyond standard chemo- or radiation therapies have shown promising results in both pre-clinical and clinical settings. Some of these approaches include stem cell therapy, new pharmaceuticals and nutraceuticals, and the use of tumor specific peptides or GB-targeted antibodies and immune-based therapies. A common limitation in the efficacy of these treatments is the inability of these therapeutic agents to readily cross the blood-brain barrier (BBB) to reach the tumor site. Therefore, many strategies are being developed to achieve targeted delivery of drugs across the BBB so that they can kill the cancer cells, while sparing healthy tissue. One of the most promising new approaches involves the use of nanoparticles that can carry therapeutic drugs and genes across the BBB and home in on the GB tumor site.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.